Another possibility, explaining the tumor susceptibility of BRCA-deficient patients is that the common genetic alterations (e.g., BRCA1 or BRCA2 mutations) are regularly associated with loss of wild-type p53 (Ramus et al., 1999), ATM (Tommiska et al., 2008), or CHK2 (Cao et al., 2006). The gene discussed is BRCA1; the disease is neoplasm.